- ARGX Q2 2026: sales up 60% year‑over‑year. Company credits expanded Vyvgart indications and pipeline progress. Global Vyvgart product sales higher versus Q2 2025.
- argenx expanded U.S. VYVGART and VYVGART Hytrulo labeling to cover all gMG serotypes (AChR, MuSK, LRP4, seronegative); company will seek ocular myasthenia gravis label after ADAPT OCULUS results
TradingView
Key facts: argenx Q2 sales +60%; Vyvgart labeled for all gMG serotypes
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- EURONEXT:ARGX
- Language
- English (India)
ARGX Q2 2026: sales up 60% year‑over‑year. Company credits expanded Vyvgart indications and pipeline progress. Global Vyvgart product sales higher versus Q2 2025.argenx expanded U.